Andor Health’s ThinkAndor Advances AI-Native Connected Care
ORLANDO, Fla., July 30, 2026 Andor Health announced that its AI-native clinical services operating platform, ThinkAndor®, has reached General...
patient access
Advertisement
Halozyme Reaffirms Long-Term Royalty Growth Despite Proposed Medicare Pricing Changes
SAN DIEGO, June 15, 2026 Halozyme Therapeutics, Inc. has confirmed that it expects zero to minimal impact on royalty...
Vanda Urges FDA to Reject Extended Drug Review Timelines
WASHINGTON, April 9, 2026 Vanda Pharmaceuticals Inc. has publicly called on the U.S. Food and Drug Administration (FDA) to...
Physician Shortage Strains U.S. Healthcare Systems, Report Finds
WINDHAM, New Hampshire | January 6, 2026 — Medicus Healthcare Solutions has released a comprehensive new report examining the...
Novartis Launches Flagship U.S. Hub to Secure Drug Manufacturing
EAST HANOVER, N.J. — December 12, 2025 — Novartis, a global innovative medicines company, has officially broken ground on...
Advertisements
Scemblix® Gets Priority Access Under Ontario’s FAST Program
MONTREAL, QC, Dec. 10, 2025 — Scemblix® (asciminib) has become one of the first therapies prioritized for public reimbursement...
Biocon Biologics Expands Insulin Glargine Access in U.S.
BRIDGEWATER, N.J., and BENGALURU, India – October 16, 2025: Biocon Biologics Ltd., a global leader in biosimilars, has expanded...
BioCryst Acquires Astria Therapeutics to Expand HAE Pipeline
BOSTON – October 14, 2025 – BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and Astria Therapeutics, Inc. (NASDAQ: ATXS) announced a...
Kedrion Biopharma Launches YIMMUGO® for PI in the U.S.
FORT LEE, N.J., October 9, 2025 — Kedrion Biopharma today announced the U.S. commercial launch of YIMMUGO® (Immune Globulin...
Kedrion Biopharma Secures FDA Nod for QIVIGY® and Expands U.S. Growth Plan
September 29, 2025 – Kedrion Biopharma announced a major regulatory and strategic milestone with the U.S. Food and Drug...
Advertisement
